INDICATIONS AND USAGE
ESTRACE (estradiol vaginal cream, USP, 0.01%) is indicated in the treatment of vulvar and vaginal atrophy.
DOSAGE AND ADMINISTRATION
Use of ESTRACE (estradiol vaginal cream, USP, 0.01%), alone or in combination with a progestin, should begiven and administered to the shortest duration consistent with treatment care plan and risks for the individual woman. Patients, together with their respective physicians should reevaluate periodically as clinically appropriate (for example, 3-month to 6-month intervals) to determine if treatment is still necessary. For treatment and management of vulvar and vaginal atrophy associated with the menopauseand other related factors, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.